{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:01:03Z","timestamp":1750204863242,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["18K07885"],"award-info":[{"award-number":["18K07885"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s12185-019-02782-z","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:01:43Z","timestamp":1574082103000},"page":"369-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system"],"prefix":"10.1007","volume":"111","author":[{"given":"Yuto","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Yada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ogiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruto","family":"Shimonishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Midori","family":"Shima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,18]]},"reference":[{"key":"2782_CR1","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","volume":"4","author":"JE Sadler","year":"2006","unstructured":"Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost. 2006;4:2103\u201314.","journal-title":"J Thromb Haemost."},{"key":"2782_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1053\/beha.2001.0138","volume":"14","author":"C Mazurier","year":"2001","unstructured":"Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Meyer D. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol. 2001;14:337\u201347.","journal-title":"Best Pract Res Clin Haematol."},{"key":"2782_CR3","first-page":"837906","volume":"2013","author":"S Dukka","year":"2013","unstructured":"Dukka S, Allsup DJ. Perioperative management of type 2N Von Willebrand's disease with recombinant factor viii in a patient undergoing knee-replacement surgery. Case Rep Hematol. 2013;2013:837906.","journal-title":"Case Rep Hematol."},{"key":"2782_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1160\/TH12-04-0244","volume":"108","author":"EM de Wee","year":"2012","unstructured":"de Wee EM, Sanders YV, Mauser-Bunschoten EP, van der Bom JG, Degenaar-Dujardin ME, Eikenboom J, et al. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost. 2012;108:683\u201392.","journal-title":"Thromb Haemost."},{"key":"2782_CR5","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1111\/j.1538-7836.2012.04923.x","volume":"10","author":"N Rydz","year":"2012","unstructured":"Rydz N, James PD. The evolution and value of bleeding assessment tools. J Thromb Haemost. 2012;10:2223\u20139.","journal-title":"J Thromb Haemost."},{"key":"2782_CR6","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/j.1538-7836.2006.01847.x","volume":"4","author":"A Tosetto","year":"2006","unstructured":"Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4:766\u201373.","journal-title":"J Thromb Haemost."},{"key":"2782_CR7","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1182\/blood.V94.3.968.415a13_968_975","volume":"94","author":"S Tsuji","year":"1999","unstructured":"Tsuji S, Sugimoto M, Miyata S, Kuwahara M, Kinoshita S, Yoshioka A. Real-time analysis of mural thrombus formation in various platelet aggregation disorders: distinct shear-dependent roles of platelet receptors and adhesive proteins under flow. Blood. 1999;94:968\u201375.","journal-title":"Blood"},{"key":"2782_CR8","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood-2002-03-0944","volume":"101","author":"M Sugimoto","year":"2003","unstructured":"Sugimoto M, Matsui H, Mizuno T, Tsuji S, Miyata S, Matsumoto M, et al. Mural thrombus generation in type 2A and 2B von Willebrand disease under flow conditions. Blood. 2003;101:915\u201320.","journal-title":"Blood"},{"key":"2782_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/hae.12610","volume":"21","author":"K Ogiwara","year":"2015","unstructured":"Ogiwara K, Nogami K, Hosokawa K, Ohnishi T, Matsumoto T, Shima M. Comprehensive evaluation of haemostatic function in von Willebrand disease patients using a microchip-based flow chamber system. Haemophilia. 2015;21:71\u201380.","journal-title":"Haemophilia"},{"key":"2782_CR10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/jth.13273","volume":"14","author":"K Nogami","year":"2016","unstructured":"Nogami K, Ogiwara K, Yada K, Shida Y, Takeyama M, Yaoi H, et al. Assessing the clinical severity of type 1 von WIllebrand disease patients with a microchip flow-chamber system. J Thromb Haemost. 2016;14:667\u201374.","journal-title":"J Thromb Haemost."},{"key":"2782_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1160\/TH16-06-0430","volume":"117","author":"A \u00c5gren","year":"2017","unstructured":"\u00c5gren A, Holmstr\u00f6m M, Schmidt DE, Hosokawa K, Blomb\u00e4ck M, Hjemdahl P. Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system. Thromb Haemost. 2017;117:75\u201385.","journal-title":"Thromb Haemost."},{"key":"2782_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0925-5710(96)00470-7","volume":"64","author":"M Nishino","year":"1996","unstructured":"Nishino M, Nishino S, Sugimoto M, Shibata M, Tsuji S, Yoshioka A. Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy. Int J Hematol. 1996;64:127\u201334.","journal-title":"Int J Hematol."},{"key":"2782_CR13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1055\/s-0037-1614572","volume":"81","author":"M Shibata","year":"1999","unstructured":"Shibata M, Shima M, Fujimura Y, Takahashi Y, Nakai H, Sakurai Y, et al. Identification of the binding site for an alloantibody to von Willebrand factor which inhibits binding to glycoprotein Ib within the amino-terminal region flanking the A1 domain. Thromb Haemost. 1999;81:793\u20138.","journal-title":"Thromb Haemost"},{"key":"2782_CR14","first-page":"306","volume":"34","author":"DE Macfarlane","year":"1975","unstructured":"Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh. 1975;34:306\u20138.","journal-title":"Thromb Diath Haemorrh."},{"key":"2782_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/978-1-4939-7196-1_20","volume":"1646","author":"E Duncan","year":"2017","unstructured":"Duncan E, Rodgers S. One-stage factor VIII Assays. Methods Mol Biol. 2017;1646:247\u201363.","journal-title":"Methods Mol Biol."},{"key":"2782_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1182\/blood.V77.1.113.113","volume":"77","author":"Y Fujimura","year":"1991","unstructured":"Fujimura Y, Usami Y, Titani K, Niinomi K, Nishio K, Takase T, et al. Studies on anti-von Willebrand factor (vWF) monoclonal antibody NMC-4, which inhibits both ristocetin- and botrocetin-induced vWF binding to platelet glycoprotein Ib. Blood. 1991;77:113\u201320.","journal-title":"Blood"},{"key":"2782_CR17","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/jth.13118","volume":"13","author":"K Yada","year":"2015","unstructured":"Yada K, Nogami K, Takeyama M, Ogiwara K, Wakabayashi H, Shima M. Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity. J Thromb Haemost. 2015;13:1843\u201353.","journal-title":"J Thromb Haemost."},{"key":"2782_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1182\/blood-2006-05-021105","volume":"109","author":"PD James","year":"2007","unstructured":"James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood. 2007;109:145\u201354.","journal-title":"Blood"},{"key":"2782_CR19","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/jth.12348","volume":"11","author":"M Bowman","year":"2013","unstructured":"Bowman M, Lillicrap D, James P. The genetics of Canadian type 3 von Willebrand disease: further evidence for codominant inheritance of mutant alleles: a reply to a rebuttal. J Thromb Haemost. 2013;11:1786\u20137.","journal-title":"J Thromb Haemost."},{"key":"2782_CR20","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/j.1538-7836.2011.04464.x","volume":"9","author":"K Hosokawa","year":"2011","unstructured":"Hosokawa K, Ohnishi T, Kondo T, Furukawa M, Koide T, Maruyama I, et al. A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J Thromb Haemost. 2011;9:2029\u201337.","journal-title":"J Thromb Haemost."},{"key":"2782_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S1079-9796(03)00033-0","volume":"30","author":"L Baronciani","year":"2003","unstructured":"Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, et al. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis. 2003;30:264\u201370.","journal-title":"Blood Cells Mol Dis."},{"key":"2782_CR22","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/jth.12987","volume":"13","author":"S Furukawa","year":"2015","unstructured":"Furukawa S, Nogami K, Ogiwara K, Yada K, Minami H, Shima M. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry. J Thromb Haemost. 2015;13:1279\u201384.","journal-title":"J Thromb Haemost."},{"key":"2782_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/hae.12733","volume":"21","author":"ME van Meegeren","year":"2015","unstructured":"van Meegeren ME, Mancini TL, Schoormans SC, van Haren BJ, van Duren C, Diekstra A, et al. Clinical phenotype in genetically confirmed von Willebrand disease type 2N patients reflects a haemophilia A phenotype. Haemophilia. 2015;21:375\u201383.","journal-title":"Haemophilia"},{"key":"2782_CR24","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1182\/blood.V80.4.988.988","volume":"80","author":"E Fressinaud","year":"1992","unstructured":"Fressinaud E, Sakariassen KS, Rothschild C, Baumgartner HR, Meyer D. Shear rate-dependent impairment of thrombus growth on collagen in nonanticoagulated blood from patients with von Willebrand disease and haemophilia. Blood. 1992;80:988\u201394.","journal-title":"Blood"},{"key":"2782_CR25","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1365-2516.2012.02867.x","volume":"18","author":"S Ogawa","year":"2012","unstructured":"Ogawa S, Szlam F, Dunn AL, Bolliger D, Ohnishi T, Hosokawa K, et al. Evaluation of a novel flow chamber system to assess clot formation in factor FVIII-deficient mouse and anti-factor IXa-treated human blood. Haemophilia. 2012;18:926\u201332.","journal-title":"Haemophilia"},{"key":"2782_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3324\/haematol.2012.077263","volume":"98","author":"G Castaman","year":"2013","unstructured":"Castaman G, Goodeve A, Eikenboom J. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica. 2013;98:667\u201374.","journal-title":"Haematologica"},{"key":"2782_CR27","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1055\/s-0031-1281031","volume":"37","author":"DJ Hampshire","year":"2011","unstructured":"Hampshire DJ, Goodeve AC. The international society on thrombosis and haematosis von Willebrand disease database: an update. Semin Thromb Hemost. 2011;37:470\u20139.","journal-title":"Semin Thromb Hemost."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02782-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02782-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02782-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:44:31Z","timestamp":1605573871000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02782-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,18]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["2782"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02782-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2019,11,18]]},"assertion":[{"value":"30 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}